Archive October 16, 2019 Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Archive October 2, 2019 Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer
Archive September 30, 2019 Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Archive September 25, 2019 Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference
Archive September 5, 2019 Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress
Archive September 3, 2019 Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Archive August 19, 2019 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Archive August 14, 2019 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Archive August 13, 2019 Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
